Pyruvate promotes tumor angiogenesis through HIF-1-dependent PAI-1 expression

International Journal of Oncology

Volumn 38, Issue 2, 2011, Pages 571-576

  Jung, Seung Youn ^a   Song, Hyun Seok ^a   Park, Shi Young ^a   Chung, Soo Hak ^a   Kim, Yung Jin ^a  

^a Pusan National University   (South Korea)

Author keywords

Angiogenesis; Hypoxia inducible factor 1 ; Plasminogen activator inhibitor 1; Pyruvate

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA RESPONSE ELEMENT 2; NUCLEAR PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRUVIC ACID; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; UPREGULATION;

ANOXIA; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELLS, CULTURED; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENDOTHELIUM, VASCULAR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROMOTER REGIONS, GENETIC; PYRUVIC ACID; RESPONSE ELEMENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION, GENETIC; UMBILICAL VEINS;

EID: 78651242580     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2010.859     Document Type: Article

References (40)

1. Kroemer G and Pouyssegur J: Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13: 472-482, 2008.
2. Gatenby RA and Gillies RJ: Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891-899, 2004.
3. Kim JW, Gao P and Dang CV: Effects of hypoxia on tumor metabolism. Cancer Metastasis Rev 26: 291-298, 2007.
4. Lu H, Forbes RA and Verma A: Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 277: 23111-23115, 2002.
5. Dang CV and Semenza GL: Oncogenic alterations of metabolism. Trends Biochem Sci 24: 68-72, 1999.
6. Galarraga J, Loreck DJ, Graham JF, et al: Glucose metabolism in human gliomas: correspondence of in situ and in vitro metabolic rates and altered energy metabolism. Metab Brain Dis 1: 279-291, 1986.
7. Koch AE: Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 62 (Suppl. 2): S60-S67, 2003.
8. Folkman J: Angiogenesis and apoptosis. Semin Cancer Biol 13: 159-167, 2003.
9. Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410, 2003.
10. Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S and Distler O: Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 47: 149-161, 2003.
11. North S, Moenner M and Bikfalvi A: Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. Cancer Lett 218: 1-14, 2005.
12. Lee MS, Moon EJ, Lee SW, Kim MS, Kim KW and Kim YJ: Angiogenic activity of pyruvic acid in in vivo and in vitro angiogenesis models. Cancer Res 61: 3290-3293, 2001.
13. Riccio A, Lund LR, Sartorio R, et al: The regulatory region of the human plasminogen activator inhibitor type-1 (PAI-1) gene. Nucleic Acids Res 16: 2805-2824, 1988.
14. Liu Q, Moller U, Flugel D and Kietzmann T: Induction of plasminogen activator inhibitor I gene expression by intracellular calcium via hypoxia-inducible factor-1. Blood 104: 3993-4001, 2004.
15. Tacchini L, Matteucci E, De Ponti C and Desiderio MA: Hepatocyte growth factor signaling regulates transactivation of genes belonging to the plasminogen activation system via hypoxia inducible factor-1. Exp Cell Res 290: 391-401, 2003.
16. Fink T, Kazlauskas A, Poellinger L, Ebbesen P and Zachar V: Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1. Blood 99: 2077-2083, 2002.
17. Agirbasli M: Pivotal role of plasminogen-activator inhibitor 1 in vascular disease. Int J Clin Pract 59: 102-106, 2005.
18. Ulisse S, Baldini E, Sorrenti S and D'Armiento M: The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets 9: 32-71, 2009.
19. Devy L, Blacher S, Grignet-Debrus C, et al: The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 16: 147-154, 2002.
20. Bajou K, Masson V, Gerard RD, et al: The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 152: 777-784, 2001.
21. Waltz DA, Natkin LR, Fujita RM, Wei Y and Chapman HA: Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 100: 58-67, 1997.
22. Providence KM and Higgins PJ: PAI-1 expression is required for epithelial cell migration in two distinct phases of in vitro wound repair. J Cell Physiol 200: 297-308, 2004.
23. Binder BR, Mihaly J and Prager GW: uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 97: 336-342, 2007.
24. Cullen JP, Nicholl SM, Sayeed S, et al: Plasminogen activator inhibitor-1 deficiency enhances flow-induced smooth muscle cell migration. Thromb Res 114: 57-65, 2004.
25. Soff GA, Sanderowitz J, Gately S, et al: Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 96: 2593-2600, 1995.
26. Eitzman DT, Krauss JC, Shen T, Cui J and Ginsburg: Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood 87: 4718-4722, 1996.
27. Kietzmann T, Roth U and Jungermann K: Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood 94: 4177-4185, 1999.
28. Lau CK, Yang ZF, Lam CT, Tam KH, Poon RT and Fan ST: Suppression of hypoxia inducible factor-1alpha (HIF-1alpha) by YC-1 is dependent on murine double minute 2 (Mdm2). Biochem Biophys Res Commun 348: 1443-1448, 2006.
29. Yeo EJ, Chun YS, Cho YS, et al: YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95: 516-525, 2003.
30. Shin DH, Kim JH, Jung YJ, et al: Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading. Cancer Lett 255: 107-116, 2007.
31. Lijnen HR: Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 3: 35-45, 2005.
32. Booth NA: Fibrinolysis and thrombosis. Baillieres Best Pract Res Clin Haematol 12: 423-433, 1999.
33. Yamamoto K, Takeshita K, Shimokawa T, et al: Plasminogen activator inhibitor-1 is a major stress-regulated gene: implications for stress-induced thrombosis in aged individuals. Proc Natl Acad Sci USA 99: 890-895, 2002.
34. Mazar AP, Henkin J and Goldfarb RH: The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis 3: 15-32, 1999.
35. He G, Bruun JM, Lihn AS, Pedersen SB and Richelsen B: Stimulation of PAI-1 and adipokines by glucose in human adipose tissue in vitro. Biochem Biophys Res Commun 310: 878-883, 2003.
36. Kortlever RM, Higgins PJ and Bernards R: Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 8: 877-884, 2006.
37. Knowles HJ, Mole DR, Ratcliffe PJ and Harris AL: Normoxic stabilization of hypoxia-inducible factor-1alpha by modulation of the labile iron pool in differentiating U937 macrophages: effect of natural resistance-associated macrophage protein 1. Cancer Res 66: 2600-2607, 2006.
38. 2- regulated gene expression. FASEB J 16: 1151-1162, 2002.
39. Zagorska A and Dulak J: HIF-1: the knowns and unknowns of hypoxia sensing. Acta Biochim Pol 51: 563-585, 2004.
40. Lu H, Dalgard CL, Mohyeldin A, McFate T, Tait AS and Verma A: Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J Biol Chem 280: 41928-41939, 2005.